

Marc Maliepaard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3521392/publications.pdf>

Version: 2024-02-01

15
papers

392
citations

1478505

6
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

539
citing authors

#	ARTICLE	IF	CITATIONS
1	The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 31-59.	4.0	224
2	Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 103-115.	46.4	66
3	Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1007-1016.	1.9	24
4	Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 979-990.	1.9	18
5	A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 667-678.	2.4	18
6	Requirements for generic anti-epileptic medicines: a regulatory perspective. <i>Journal of Neurology</i> , 2009, 256, 1966-1971.	3.6	7
7	Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 966-973.	4.7	6
8	Pharmacokinetics and Generic Drug Switching: A Regulator's View. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1065-1069.	3.5	6
9	Interchangeability of Generics – Experiences and Outlook Toward Pharmacokinetics Variability and Generic-Generic Substitution. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 292-294.	4.7	4
10	Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	4
11	Impact of the new European Union <i>In Vitro</i> Diagnostics Regulation on the practice of hospital diagnostic laboratories. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 583-590.	3.1	4
12	Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?. <i>Pharmaceutical Medicine</i> , 2019, 33, 407-416.	1.9	3
13	Comment on – Levothyroxine® New and Old Formulations: Are they Switchable for Millions of Patients?. <i>Clinical Pharmacokinetics</i> , 2020, 59, 281-282.	3.5	3
14	Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands. <i>Clinical and Translational Science</i> , 2020, 13, 599-607.	3.1	3
15	Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 338-349.	4.7	2